Daichi Fujimoto

Wakayama Medical University

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects

Lung Cancer

Research Interests

Daichi Fujimoto has a total of 391 co-authors. Here are the top co-authors by number of shared publications:

Motohiro Tamiya
Osaka International Cancer Institute, Osaka, Japan
36 shared publications
Toshiyuki Kozuki
NHO Shikoku Cancer Center, 160 Ko, Minamiumemotomachi, Matsuyama, Ehime 791-0245, Japan
36 shared publications
Yuko Oya
Department of Respiratory Medicine Fujita Health University School of Medicine Toyoake, Aichi Japan
36 shared publications
Daiko Matsuoka
14Eisai Co., Ltd., Tokyo, Japan
35 shared publications
Haruki Kobayashi
Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan
35 shared publications
Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
35 shared publications

Latest Publications

Sort by

Website
Google Scholar
Cited by 1
- 3 July 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial
by Daichi Fujimoto, Mitsuhiro Abe, Kenta Murotani, Mihoko Imaji Onishi, Yuki Sato, Eisaku Miyauchi, Eri Takase, Hisashi Tanaka, Takashi Kijima, Yoshihiko Taniguchi, et al.
Rationale: Optimal corticosteroid treatment duration for immune checkpoint inhibitor (ICI)–related pneumonitis remains uncertain. No randomized trials have addressed this issue. Objectives: To determine whether a 3-week corticosteroid taper is noninferior to the guideline-recommended 6-week taper for short-term treatment success in patients with mild (Common Terminology Criteria for Adverse Events grade 1-2) immune-related pneumonitis. Methods: Patients with mild immune-related pneumonitis were assigned to either a 3-week or 6-week corticosteroid regimen. The primary endpoint was the treatment success rate at 8 weeks, defined as resting room-air SpO2 ≥ 90% without steroid escalation or prolongation due to pneumonitis worsening. Measurements and main results: Overall, 106 patients were randomly assigned (median age = 72 years; grade 2, 73%). Treatment success rates were 66.7% and 85.2% in the 3- and 6-week groups, respectively, which did not demonstrate noninferiority (difference = −18.5 percentage points; 80% CI, −29.0% to −7.9%; P = .621) of the 3-week regimen. A predefined exploratory analysis indicated superiority of the 6-week regimen (P = .013). Grade ≥3 adverse events occurred in 12% and 24% of the 3- and 6-week groups, respectively; however, all were manageable with clinical interventions. The total quality of life mean change using the King’s Brief Interstitial Lung Disease score from baseline was 4.78 and 6.28 in the 3- and 6-week groups, respectively (between-group difference = −1.50 percentage points; 95% confidence interval, −5.91 to 2.91). Overall survival was comparable between the groups (hazard ratio = 1.03; 95% CI, 0.46-2.29; P = .95). Conclusions: This study establishes the 6-week corticosteroid regimen as an evidence-based standard for treating ICI-related pneumonitis.
Website
Google Scholar
- 3 July 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial
by Daichi Fujimoto, Mitsuhiro Abe, Kenta Murotani, Mihoko Imaji Onishi, Yuki Sato, Eisaku Miyauchi, Eri Takase, Hisashi Tanaka, Takashi Kijima, Yoshihiko Taniguchi, et al.
Rationale: Optimal corticosteroid treatment duration for immune checkpoint inhibitor (ICI)–related pneumonitis remains uncertain. No randomized trials have addressed this issue. Objectives: To determine whether a 3-week corticosteroid taper is noninferior to the guideline-recommended 6-week taper for short-term treatment success in patients with mild (Common Terminology Criteria for Adverse Events grade 1-2) immune-related pneumonitis. Methods: Patients with mild immune-related pneumonitis were assigned to either a 3-week or 6-week corticosteroid regimen. The primary endpoint was the treatment success rate at 8 weeks, defined as resting room-air SpO2 ≥ 90% without steroid escalation or prolongation due to pneumonitis worsening. Measurements and main results: Overall, 106 patients were randomly assigned (median age = 72 years; grade 2, 73%). Treatment success rates were 66.7% and 85.2% in the 3- and 6-week groups, respectively, which did not demonstrate noninferiority (difference = −18.5 percentage points; 80% CI, −29.0% to −7.9%; P = .621) of the 3-week regimen. A predefined exploratory analysis indicated superiority of the 6-week regimen (P = .013). Grade ≥3 adverse events occurred in 12% and 24% of the 3- and 6-week groups, respectively; however, all were manageable with clinical interventions. The total quality of life mean change using the King’s Brief Interstitial Lung Disease score from baseline was 4.78 and 6.28 in the 3- and 6-week groups, respectively (between-group difference = −1.50 percentage points; 95% confidence interval, −5.91 to 2.91). Overall survival was comparable between the groups (hazard ratio = 1.03; 95% CI, 0.46-2.29; P = .95). Conclusions: This study establishes the 6-week corticosteroid regimen as an evidence-based standard for treating ICI-related pneumonitis.
Cited by 1
Open Access
Website
Google Scholar
- 7 March 2026
- Published by Elsevier in International Journal of Lung Cancer
Clinical course of non-small cell lung cancer with concurrent MET exon 14 skipping and KRAS G12C mutations treated with sequential targeted therapies: a case report
by Yu Hasegawa, Daichi Fujimoto, Tetsushi Maesako, Mayuko Tokuda, Tomoki Higashiyama, Akio Tada, Yoshiki Negi, Taiichiro Otsuki, Koji Mikami, Ryo Takahashi, et al.
Website
Google Scholar
- 7 March 2026
- Published by Elsevier in International Journal of Lung Cancer
Open Access
Clinical course of non-small cell lung cancer with concurrent MET exon 14 skipping and KRAS G12C mutations treated with sequential targeted therapies: a case report
by Yu Hasegawa, Daichi Fujimoto, Tetsushi Maesako, Mayuko Tokuda, Tomoki Higashiyama, Akio Tada, Yoshiki Negi, Taiichiro Otsuki, Koji Mikami, Ryo Takahashi, et al.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 2: Primer sequences for PCR.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 2 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 2: Primer sequences for PCR.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 3: characteristics of four RET-aberrant cancer cells.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 3 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 3: characteristics of four RET-aberrant cancer cells.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 7: Nuclear and cytoplasm YAP expression in 23 patients with RET fusion positive NSCLC.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 7 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 7: Nuclear and cytoplasm YAP expression in 23 patients with RET fusion positive NSCLC.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 5: 753 genes upregulated significantly in TPC-1 cells treated with selpercatinib for 48 h.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 5 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 5: 753 genes upregulated significantly in TPC-1 cells treated with selpercatinib for 48 h.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 1: Details of the antibodies used in this study.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 1 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 1: Details of the antibodies used in this study.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 6: Characteristics of patients with RET-fusion positive NSCLC.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 6 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 6: Characteristics of patients with RET-fusion positive NSCLC.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 4: 3924 genes upregulated significantly in LC-2/ad cells treated with selpercatinib for 48 h.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 4 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Supplementary Table 4: 3924 genes upregulated significantly in LC-2/ad cells treated with selpercatinib for 48 h.
Open Access
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1-11 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.
Website
Google Scholar
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 1-11 from YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
by Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, et al.

Show all